Clinical trials: Rejection
Graft Rejection, Kidney Transplant
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
This study will look at the effect on long-term kidney function using tacrolimus right after a transplant and then switching to sirolimus at 3 to 5 months after the transplant.
- Conditions
- Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
- Trial name
- NCT00895583
- Testing
- Tacrolimus, Sirolimus
- Where
- 44 sites in United States, Argentina and 5 more
- Volunteers
- 254 people
- Sponsor
- Pfizer
Graft Rejection
Molecular HistoMx Assessment for Kidney Transplant Rejection and Management
Transcriptomic analysis of kidney biopsies has demonstrated the potential to improve diagnosis of graft rejection. Molecular assessment of kidney graft rejection based on the Banff Human Organ Transplant consensus gene panel is…
- Trial name
- NCT07347353
- Testing
- No intervention
- Where
- 2 sites in France
- Volunteers
- 400 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Acute Graft Rejection, Diabetes
A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
While the incidence of acute rejection and early graft loss have improved dramatically with the advent of newer immunosuppressant medications, improvements in long-term patient and allograft survival after kidney transplantation…
- Trial name
- Astellas (NCT01265537)
- Testing
- Tacrolimus
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
End-Stage Renal Disease, End Stage Renal Disease on Dialysis
CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk
This clinical trial investigates the transplantation of donor kidneys that have been genetically modified ex vivo using CRISPR-Cas9 genome editing to reduce immunogenicity and transplant rejection.
- Conditions
- End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant, Kidney Transplant Rejection
- Trial name
- NCT07053462
- Testing
- Ex Vivo CRISPR-Cas9 Gene Editing of Donor Kidney, Kidney Transplantation with Standard Care
- Where
- China
- Volunteers
- 90 people
- Sponsor
- AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Kidney Transplant Rejection
Tacrolimus Exposure in Kidney Transplantation
Using CDW data from 5 tertiary hospitals in Korea, this study identify the optimal range of trough level that can prevent adverse outcome in the early periods after transplantation.
- Trial name
- NCT06348446
- Where
- 4 sites in South Korea
- Volunteers
- 12,000 people
- Sponsor
- Seoul National University Hospital
Renal Transplant Rejection, Immune Repertoire
ALLoreactive T-Cell receptOr RePertoire in kidnEy tranSplantation
In this study, the investigators will establish a workflow to generate unique patterns of the donor-reactive T cell repertoire using mixed lymphocyte reactions to select alloreactive T cell clones prior to transplantation Tissue…
- Conditions
- Renal Transplant Rejection, Immune Repertoire, Transplant; Complication, Rejection, Alloreactivity
- Trial name
- ALL-T-COPIES (NCT03422224)
- Testing
- Mixed lymphocyte reaction
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Vienna
Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis
EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
The purpose of this study is to assess the efficacy and safety of the study drug, known as "ATG Fresenius S," which is sometimes called "EZ-2053," to prevent a lung transplant patient's body from rejecting a transplanted lung or…
- Conditions
- Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis
- Trial name
- NCT00105183
- Testing
- EZ-2053, EZ-2053 5mg/kg
- Where
- 19 sites in United States, Australia and 2 more
- Volunteers
- 223 people
- Sponsor
- Neovii Biotech
Heart Diseases, Heart Transplantation
Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens
The purpose of this study is to assess the safety and efficacy of tacrolimus in de novo heart transplantation.
- Trial name
- NCT00157014
- Testing
- Tacrolimus, Cyclosporine, Mycophenolate mofetil
- Where
- 13 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Astellas Pharma Inc
Heart Transplantation
Superiority Assessment of Donor-derived Cell-FreE DNA ( Deoxyribonucleic Acid) for Cardiac Allograft REjection Monitoring
Heart transplantation (HTx) remains the gold-standard treatment for patients with end-stage heart failure refractory to the medical management, offering the best survival and quality of life.
- Trial name
- SAFE-CARE (NCT07897526)
- Testing
- non-invasive strategy based of the analysis of circulating dd-cfDNA (AlloSeq cfDNA assay), control
- Volunteers
- 352 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver Transplant Rejection
The TOGETHER Project - Liver
To validate the use of a RNAseq-based peripheral blood assay in liver transplant recipients when correlated to liver biopsy results.
- Trial name
- TOGETHER (NCT03874286)
- Testing
- Liver Transplant
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Mayo Clinic
Antibody-mediated Rejection, Humoral Rejection
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
This is an open-label analysis that will compare eculizumab versus Plasmapheresis (PP) and Immunoglobulin (IVIg) for the treatment of antibody-mediated rejection (AMR) in renal transplant recipients.
- Trial name
- NCT01895127
- Testing
- Eculizumab, Immunoglobulin, Plasmapheresis
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brigham and Women's Hospital
Complication of Transplanted Liver
Donor Specific HLA Alloantibodies in Liver Transplantation
The aim is to evaluate the impact of donor specific HLA alloantibodies (DSA) on all-cause mortality and re-transplantation, early allograft dysfunction, acute and chronic rejection, fibrosis, vascular, and biliary complications.
- Trial name
- NCT02784080
- Testing
- HLA-alloantibodies exposure
- Where
- 5 sites in Denmark, Finland and 2 more
- Volunteers
- 858 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Autoimmune Diseases, Inflammation
Prospective Study of White Blood Cells
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.
- Conditions
- Autoimmune Diseases, Inflammation, Rejection; Transplant, Liver
- Trial name
- NCT04838171
- Testing
- White blood cell and blood collection
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Quell Therapeutics Limited
Kidney Transplant Failure and Rejection, Immunosuppression-related Infectious Disease
Tacrolimus Pharmacokinetic Subpopulations
This prospective study will investigate the concentrations of tacrolimus metabolites (M-I and M-III) over the four first years post-transplantation.
- Trial name
- TIPS (NCT04526431)
- Testing
- Dosage Forms Oral
- Where
- 2 sites in France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Grenoble
Liver Transplant Rejection, Kidney Transplant; Complications
VOCs in Kidney and Liver Transplants
Kidney and liver trasplants represent very challenging lifesaving and effective surgical procedures for patients with end-stage kidney and/or liver disease.
- Trial name
- NCT04514666
- Testing
- Breath analysis
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Societa Italiana di Chirurgia ColoRettale
Acute Rejection
Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients
Acute kidney allograft rejection is the major cause for a loss of graft function and has a negative impact on long-term graft survival.
- Trial name
- RIACT (NCT01117662)
- Testing
- Rituximab
- Where
- 14 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Hannover Medical School
Kidney Transplant Rejection
Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R)
Antibody mediated rejection (ABMR) is a major cause of graft loss after kidney transplantation (KT) and is mainly associated with preformed anti-HLA donor specific antibodies (DSAs) (phenotype 1) or de novo DSAs (dnDSAs)…
- Trial name
- BELA-M-R (NCT06291103)
- Testing
- Conversion to Belatacep, Standard of care treatment (SOC regimen) with Tacrolimus
- Where
- France
- Volunteers
- 290 people
- Sponsor
- University Hospital, Rouen
Kidney Transplantation
A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients
An open-label study to assess the safety, tolerability, and efficacy of FCR001 cell therapy in adult recipients 3-12 months after kidney transplantation from a living donor.
- Trial name
- FREEDOM-2 (NCT01649388)
- Testing
- FCR001
- Where
- 3 sites in United States
- Sponsor
- Talaris Therapeutics Inc.
Antibody-mediated Rejection
TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
This multi-center study is an investigator-driven randomized controlled parallel group open-label clinical trial designed to evaluate the efficacy of addition of anti-IL-6 antibody tocilizumab (TCZ) to the standard of care (SOC)…
- Trial name
- INTERCEPT (NCT04561986)
- Testing
- Tocilizumab
- Where
- 6 sites in Spain, Sweden
- Volunteers
- 50 people
- Sponsor
- Vastra Gotaland Region
Posttransplant Diabetes Mellitus, Acute Graft Rejection
Silymarin's Advantage on Graft Effectiveness
The study examines the impact of silymarin supplementation during the early post-transplant period, administering 900 g daily for 30 days under standard treatment.
- Conditions
- Posttransplant Diabetes Mellitus, Acute Graft Rejection, Biopsy Proven Acute Rejection, Antibody Mediated Rejection of Kidney Transplant
- Trial name
- SAGE (NCT06801886)
- Testing
- Silymarine supplementation
- Where
- Slovakia
- Volunteers
- 130 people
- Sponsor
- University Hospital, Martin